

Subject Index, Volume 5

A

- Absolute risk reduction, usage of, 430
- Abstracts
 - ISPOR Fifth Annual European Congress, 443
 - ISPOR Seventh Annual International Meeting, 117
- Activity impairment, gastroesophageal reflux disease and, 106
- Advertising claims
 - misleading/unsubstantiated, 389
 - regulation of patient-reported outcomes and, 372
- Airways Questionnaire, for COPD quality-of-life assessment, 436
- Anti-hypertensive drug therapy, cost-effectiveness analyses, 359
- Aspergillosis, incidence and direct costs of, 27

B

- Bias against new innovations, in willingness-to-pay valuations, 67
- Bootstrap confidence levels, for diabetes management costs, 397

C

- Candidiasis, incidence and direct costs of, 27
- Ceiling effect, HRQL measures and, 329
- Censored LAD model, *vs.* other HRQL measures, 329
- Chronic obstructive pulmonary disease, comparative analysis of QoL measures, 436
- Clinical trials. *See also specific clinical trials*
 - analytic issues, 19
 - HRQL measures, selection of, 16
 - study design, 18
- CODE-2 (Costs of Diabetes in Europe-Type 2 study), 397
- Colorectal cancer metastatic, inpatient care, cost-analysis of, 35
- Company perspective, of pharmacogenetic testing, 10
- COPD, comparative analysis of QoL measures, 436
- Cost-analysis, of metastatic colorectal cancer inpatient care, 35
- Cost-benefit analysis, *vs.* cost-effectiveness analysis, 338
- Cost-effectiveness analysis
 - of anti-hypertensive drug therapy, 359
 - of CMV management in liver transplant patients, 347
 - of GERD long-term management, 312
 - of hepatitis B alternative therapy, 404

- of interferon beta for multiple sclerosis, 44
- of multiple sclerosis, 1
- in Stroke Outcome Model development, 82
- utility of, 71
- vs.* cost-benefit analysis, 338
- Cost-of-illness studies, multiple sclerosis, 1
- Costs of Diabetes in Europe-Type 2 study (CODE-2), 397
- Cost-utility analysis, gastroesophageal reflux disease, 312
- Cryptococcosis, incidence and direct costs of, 27
- Cytomegalovirus management, in liver transplant patients, decision making for, 347

D

- Decision making
 - for anti-hypertensive drug therapy, 359
 - CMV management in liver transplant patients, 347
 - impact of economic evaluations on, 71
 - statistical analysis for, 430
- Diabetes management costs, bootstrap confidence levels for, 397
- Direct costs
 - infantile respiratory syncytial virus infection, 55
 - systemic fungal infections, 26
- Disability, in Stroke Outcome Model development, 82
- Drug benefit design, for formulary development, 382
- Drug promotions
 - FDA actions against misleading/unsubstantiated claims, 389
 - of HRQL measures, 23
 - patient-reported outcomes and, 372
 - standardization of patient-reported outcomes and, 372

E

- Economic evaluation
 - gastroesophageal reflux disease, 312
 - impact on decision making, 71
 - of multiple sclerosis treatment, 1
 - in Stroke Outcome Model development, 82
- Economic violations, FDA actions against, 389

F

- Family financial burden, infantile respiratory syncytial virus infection, 55
- FDA. *See* Food and Drug Administration
- Federal Food, Drug, and Cosmetic Act (FFDCA), 14
- 5-Fluorouracil toxicity, hospitalization costs, 3, 35

Food and Drug Administration (FDA)
 misleading/unsubstantiated advertising claims and, 389
 regulation of product labels and advertising claims, 372
 Formulary development
 Kaiser-Permanente, 382
 Regence BlueShield, 297
 France, Stroke Outcome Model development costing method, 95
 Fungal infections, incidence and direct costs, 27
 5-FU toxicity, hospitalization costs, 3, 35

G

Gastroesophageal reflux disease (GERD)
 long-term management, 312
 work productivity and activity impairment, 106
 Gene therapy, development, 6
 Genomics, economic issues, 5
 Germany, Stroke Outcome Model development costing method, 95

H

Health-related quality of life (HRQL)
 analysis methods, comparison of, 329
 patient-reported outcomes, 295, 372
 regulatory issues, 14
 Health Utilities Index, *vs.* other HRQL measures, 329
 Heartburn. *See* Gastroesophageal reflux disease
 Hepatitis B alternative therapy, cost-effectiveness analysis, 404
 Histoplasmosis, incidence and direct costs of, 27
 Hormone replacement therapy, time-trade-off assessments, 98
 Hospital inpatient uniform bills, sepsis coding on, 79
 Hospitalization costs
 for 5-FU toxicity, 35
 for infantile respiratory syncytial virus infections, 55
 of systemic fungal infections, 27
 for vertebral fractures, 301
 HRQL. *See* Health-related quality of life
 Hypertension treatment decision making, cost-effectiveness analyses for, 359

I

ICD-9-CM sepsis diagnostic codes, on UB-92 hospital bills, 79
 Indirect costs
 of gastroesophageal reflux disease, 106
 infantile respiratory syncytial virus infection, 55
 Innovation, WTP and WTA valuations, 67
 Interferon cost-effectiveness
 for hepatitis B, 404
 for multiple sclerosis, 44

K

Kaiser-Permanente formulary development, 382

L

Lamivudine, cost-effectiveness for hepatitis B, 404
 Length-of-stay, for vertebral fractures, 301
 Liver transplantation CMV management, modeling of, 347
 Long-term care costs
 in Stroke Outcome Model development, 82
 for vertebral fractures, 301

M

Markov process analysis, interferon beta in multiple sclerosis, 44
 Migraine headaches, validation of patient perception questionnaire, 421
 Mortality, in Stroke Outcome Model development, 82
 Multiple sclerosis
 interferon beta cost-effectiveness, 44
 treatment evaluation, economic modeling studies for, 1

N

Naratriptan migraine therapy, patient perceptions of, 421
 Nebacumab, pharmacogenetic testing, 10
 NHS Economic Evaluation Database, for decision-making and, 65, 71
 Notices of violation, analysis of, 389

O

Odds ratio, usage of, 430
 Orphan drugs, 7
 Osteoporosis
 time-trade-off assessments, 98
 vertebral fractures, health care costs for, 301
 Outcomes research, results-driven, 3

P

Patient Perception of Migraine Questionnaire (PPMQ), validation of, 421
 Patient-reported outcomes
 for health-related quality of life, 295
 regulation of, 372
 Payer perspective, of pharmacogenetic testing, 9
 Pharmaceutical drugs. *See also specific drugs*
 formulary development, 382
 marketing. *See* Drug promotions
 pricing, 8
 Pharmacoeconomics, in formulary development, 297, 382
 Pharmacogenetic testing, for drug development, 8
 PhRMA Health Outcomes Committee Workshop, on HRQL regulatory issues, 14

Subject Index

Platelet aggregation inhibitors, economic evaluation in SOM development, 82
Poland, HBV alternative therapy, cost-effectiveness analysis of, 404
Post-hospitalization costs
 systemic fungal infections, 28
 vertebral fractures, 301
PPMQ (Patient Perception of Migraine Questionnaire), validation of, 421
Premature infants, respiratory syncytial virus infection costs, 55
Prescription drugs, formulary development, 297
Promotion. *See* Drug promotions
Psychometric validation, of Patient Perception of Migraine Questionnaire, 421
Public policy implications, of pharmacogenetic testing, 12

Q

Quality-adjusted life years (QALYs)
 gastroesophageal reflux disease, 312
 multiple sclerosis treatment, 44
 in women's health, 98
Quality of life assessment. *See also* Health-related quality of life
 comparative analysis for COPD, 436
 for gastroesophageal reflux disease, 106
Quality of life violations, FDA actions against, 389

R

Raloxifene, time-trade-off assessments, 98
R&D costs, revenue effects on, 6
Recurrence of stroke, in Stroke Outcome Model development, 82
Regence BlueShield, formulary development, 297
Relative risk, usage of, 430
Respiratory syncytial virus (RSV), hospitalization costs, 55

S

Sensitivity analysis
 fungal infection treatment costs, 26
 hepatitis B virus treatment costs, 404
 multiple sclerosis treatment costs, 44
Sepsis coding, on UB-92 hospital bills, 79

St. George's Respiratory Questionnaire, for COPD quality-of-life assessment, 436
Statistical analysis
 comparative, for COPD quality-of-life assessments, 436
 in decision making, 430
 models of health status, 329
Stroke Outcome Model
 costing methodology, 95
 development of, 82
Survival data, metastatic colorectal cancer, 35

T

Thrombolytic therapy, economic evaluation in SOM development, 82
Time-trade-off assessments, in women's health, 98
Tobit model, *vs.* other HRQL measures, 329
Total operating net revenue, gene therapy, 5
Trastuzumab, pharmacogenetic testing, 11

U

UB-92 hospital bills, sepsis coding on, 79
UK health-care decision makers, usefulness of economic evaluations, 71
United Kingdom, Stroke Outcome Model development costing method, 95
United States, Stroke Outcome Model development costing method, 95

V

Validation, of Patient Perception of Migraine Questionnaire, 421
Vertebral fractures, inpatient hospital and post-acute care for, 301

W

Warning letters, analysis of, 389
Willingness-to-accept valuations, new innovations and, 67
Willingness-to-pay valuations, bias against new innovations, 67
Women, vertebral fractures, inpatient hospital and post-acute care for, 301
Women's health, time-trade-off assessments, 98
Work Productivity and Activity Impairment Questionnaire, for GERD, 106